Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)

被引:161
作者
Gerstein, Hertzei C. [1 ]
机构
[1] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada
关键词
D O I
10.1016/j.ahj.2007.09.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and diabetes arise due to insufficient insulin secretion and are risk factors for cardiovascular (CV) events. Thus, targeting normal fasting glucose levels with insulin may reduce CV events. Previous studies suggest that omega-3 fatty acid supplements may reduce CV death; however, their effect in high-risk dysglycemic individuals is not known. Methods People aged >= 50 years with evidence of CV disease and with IFG, IGT, newly detected or established diabetes (on 0 or I oral agent), and a local glycated hemoglobin < 150% of the upper limit of normal for that assay were recruited and allocated to (a) either I daily injection of insulin glargine with the dose titrated to achieve a fasting plasma glucose <= 5.3 mmol/L (95 mg/dL), or standard glycemic care; and (b) either omega-3-acid ethyl esters 90 (1 g consisting of EPA 465 mg and DHA 375 mg) or identical placebo, according to a 2 x 2 factorial design. The 2 different primary outcomes for the insulin and w-3 fatty acid arms are CV events and CV death, respectively. Results A total of 12 612 (mean age 64, 35% women) people in 40 countries were randomized during a 2-year period ending December 2005. Eighty-two percent had established diabetes, 6% had new diabetes, and 12% had IGT or IFG; the, mean fasting plasma glucose was 7.3 mmol/L (131 mg/dL). Conclusions The ORIGIN trial will determine whether or not either or both of these interventions can reduce CV events.
引用
收藏
页码:26 / 32
页数:7
相关论文
共 39 条
[31]   Insulin therapy for critically ill hospitalized patients - A meta-analysis of randomized controlled trials [J].
Pittas, AG ;
Siegel, RD ;
Lau, J .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (18) :2005-2011
[32]  
Santaguida P L, 2005, Evid Rep Technol Assess (Summ), P1
[33]   Molecular and signaling mechanisms of atherosclerosis in insulin resistance [J].
Schwartz, Eric A. ;
Reaven, Peter D. .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2006, 35 (03) :525-+
[34]   INSULIN THERAPY INDUCES ANTIATHEROGENIC CHANGES OF SERUM-LIPOPROTEINS IN NONINSULIN-DEPENDENT DIABETES [J].
TASKINEN, MR ;
KUUSI, T ;
HELVE, E ;
NIKKILA, EA ;
YKIJARVINEN, H .
ARTERIOSCLEROSIS, 1988, 8 (02) :168-177
[35]  
Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5
[36]   Intensive insulin therapy in critically ill patients. [J].
Van den Berghe, G ;
Wouters, P ;
Weekers, F ;
Verwaest, C ;
Bruyninckx, F ;
Schetz, M ;
Vlasselaers, D ;
Ferdinande, P ;
Lauwers, P ;
Bouillon, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (19) :1359-1367
[37]   3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes [J].
Vehkavaara, S ;
Yki-Järvinen, H .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (02) :325-330
[38]   Insulin therapy improves endothelial function in type 2 diabetes [J].
Vehkavaara, S ;
Mäkimattila, S ;
Schlenzka, A ;
Vakkilainen, J ;
Westerbacka, J ;
Yki-Järvinen, H .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (02) :545-550
[39]   Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: Lessons from AGEing [J].
Yan, Shi Fang ;
Yan, Shi Du ;
Herold, Kevan ;
Ramsamy, Ravichandran ;
Schmidt, Ann Marie .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2006, 35 (03) :511-+